DelMar Pharmaceuticals, Inc. (DMPI) Posts Earnings Results, Misses Estimates By $0.01 EPS
DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) released its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01), Zacks reports.
Shares of DelMar Pharmaceuticals (NASDAQ DMPI) traded down $0.03 during midday trading on Tuesday, hitting $0.81. 534,300 shares of the company’s stock traded hands, compared to its average volume of 377,704. DelMar Pharmaceuticals has a 12 month low of $0.78 and a 12 month high of $5.39.
TRADEMARK VIOLATION WARNING: “DelMar Pharmaceuticals, Inc. (DMPI) Posts Earnings Results, Misses Estimates By $0.01 EPS” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/delmar-pharmaceuticals-inc-dmpi-posts-earnings-results-misses-estimates-by-0-01-eps/1703195.html.
A number of analysts recently commented on DMPI shares. Dawson James reissued a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th. Maxim Group reissued a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 16th.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.